OA12.06 First-Line Pembrolizumab or Placebo Combined with Etoposide and Platinum for ES-SCLC: KEYNOTE-604 Long-Term Follow-Up Results
Journal of Thoracic Oncology（2022）
关键词
pembrolizumab,etoposide,placebo combined,first-line,es-sclc,long-term
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要